As opposed to PTC, in which TERT promoter mutations are only found in 7.5% of tumors, 73% of ATCs hold TERT genetic alterations and they tend to co-occur with BRAF and RAS mutations, harbouring a worse prognosis [62]. Here, TERT is linked to Ehlers-Danlos syndrome, musculocontractural type.